Healthcare -
Biotechnology - NASDAQ - US
$ 0.6932
-6.3 %
$ 35.9 M
Market Cap
-0.64
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Xilio Therapeutics, Inc.
| Net Income | -58.2 M |
| Depreciation & Amortization | 1.64 M |
| Capital Expenditures | -36 K |
| Stock-Based Compensation | 6.43 M |
| Change in Working Capital | 31.8 M |
| Others | 30.3 M |
| Free Cash Flow | -18.4 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (58.2) | (76.4) | (88.2) | (75.8) | (55.2) | (17.3) |
| Depreciation & Amortization | 1.6 | 1.9 | 1.8 | 1.5 | 1.1 | 0.2 |
| Deferred Income Tax | 0 | 2.1 | 0 | 0.2 | 0.1 | (1.7) |
| Stock Based Compensation | 6.4 | 7.4 | 8.4 | 5.0 | 1.3 | 0.1 |
| Other Operating Activities | 3 K | (4.0) | 0.2 | 0.2 | 39 K | 56 K |
| Change in Working Capital | 31.8 | 0.4 | 2.0 | (11.8) | 16.6 | 0.8 |
| Cash From Operations | (18.4) | (68.6) | (75.7) | (80.8) | (36.1) | (17.8) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 36 K | (0.5) | (1.9) | (1.1) | (2.2) | (0.7) |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 36 K | (0.5) | (1.9) | (1.1) | (2.2) | (0.7) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0.2 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (3.4) | (6.8) | 85 K | (0.1) | 99 K | 10.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 25.8 | 0.2 | 16 K | 144.4 | 10.1 | 40.1 |
| Cash From Financing Activities | 29.2 | (6.5) | 69 K | 260.7 | 10.0 | 60.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 10.8 | (75.7) | (77.7) | 178.8 | (28.2) | 41.5 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (18.4) | 69.1 K | (77.6) | (81.9) | (38.3) | (18.6) |